NCT07643233尚未招募1 期
An Open-Label, Randomized, Fed, Single-Dose, Two-Sequence, Two-Period Crossover Study to Evaluate the Bioequivalence of "AJU-G721" and "G721R" in Healthy Adult Male Subjects
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 入组人数
- 36
- 试验地点
- 1
研究概览
简要总结
To evaluate and compare the safety and pharmacokinetic profiles of "AJU-G721" (test drug) and "G721R" (reference drug) in healthy adult male subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 54 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Healthy male adults aged ≥19 years and <55 years at screening.
- •Body weight ≥ 50 kg and body mass index (BMI) between 18 and 30 kg/m².
- •Clinically healthy based on medical history, physical examination, ECG, and laboratory test results, as determined by the investigator.
- •Willing and able to provide written informed consent.
- •Agrees to use medically acceptable contraception during the required study period.
排除标准
- •Use of medications known to induce or inhibit drug-metabolizing enzymes within 30 days prior to the first dose, or other medications that may interfere with the study within 10 days prior to dosing.
- •Participation in another clinical trial involving an investigational product within 6 months prior to the first dose.
- •Whole blood donation within 8 weeks or component blood donation within 2 weeks prior to the first dose.
- •History of gastrointestinal resection that may affect drug absorption.
- •Known hypersensitivity to dutasteride, tamsulosin, or any component of the investigational product.
- •History of psychiatric illness, or any condition considered unsuitable for study participation by the investigator.
研究者
研究点 (1)
Loading locations...
相似试验
招募中
1 期
Bioequivalence Study of AJU-G721 and G721R in Healthy Adult Volunteers Under Fasting ConditionsNCT07643220AJU Pharm Co., Ltd.44
已完成
1 期
Bioequivalence Study of AJU-C715 and C715R in Healthy Adult VolunteersDyslipidemiaNCT07581028AJU Pharm Co., Ltd.61
招募中
1 期
Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a New Formulation of Inclisiran Containing Polysorbate 80 Compared to the Currently Marketed FormulationNCT07626281Novartis Pharmaceuticals120
已完成
1 期
A Study to Investigate the Pharmacokinetics of Different Formulations and Safety of AZD5004 in Healthy Participants Aged 18 to 55 YearsNCT07455825AstraZeneca65
招募中
1 期
Bioequivalence Study for the Safety and the Pharmacokinetics of DWC202313, DWC202314, and DWJ1622 in Healthy Volunteers Under Fed Condition.NCT07267221Daewoong Pharmaceutical Co. LTD.36